BioArtic's BrainTransporter Collaboration With Novartis Ends Following Program Discontinuation

BioArctic said Novartis has decided to terminate an option, collaboration and license agreement signed in August 2025. The agreement was intended to explore a potential treatment combining BioArctic’s BrainTransporter technology with a Novartis proprietary asset; the provided article text gives no financial terms or further details.